InsiderTrades

Form 4 for XERS Xeris Biopharma Holdings, Inc.

Accepted 2022-02-24 00:00:00 ET · period of report 2022-02-22 · accession 0001867096-22-000025 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-02-24 2022-02-22 XERS PRESTRELSKI STEVEN CSO M - OptEx $0.69 +11.2K 581.0K +2% +$7,747
D 2022-02-24 2022-02-22 XERS PRESTRELSKI STEVEN CSO S - Sale+OE $2.42 -11.2K 569.8K -2% -$27.2K
D 2022-02-24 2022-02-22 XERS PRESTRELSKI STEVEN CSO M - OptEx $0.00 -11.2K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-02-22 M A 11,228 $0.69 581,008 D — —
2 Common Common Stock 2022-02-22 S D 11,228 $2.42 569,780 D — — (F2) $2.4188 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.36 to $2.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3 Derivative Stock Option (Right to Buy) 2022-02-22 M D 11,228 $0.00 0 D $0.69 · 2022-02-22 to 2022-02-23 11,228 Common Stock (F3) These options are fully vested as of the date hereof.